Puma Biotechnology Analyst Ratings
Puma Biotechnology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/20/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 08/04/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 06/05/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 05/05/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 03/06/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 08/05/2022 | 168.46% | HC Wainwright & Co. | $12 → $8 | Maintains | Buy |
| 05/06/2022 | 302.68% | HC Wainwright & Co. | $14 → $12 | Maintains | Buy |
| 09/28/2021 | — | Citigroup | Upgrades | Neutral → Buy | |
| 08/06/2021 | 168.46% | Goldman Sachs | $9 → $8 | Maintains | Sell |
| 08/06/2021 | 101.34% | RBC Capital | $13 → $6 | Maintains | Sector Perform |
| 08/10/2020 | 302.68% | Citigroup | $14 → $12 | Maintains | Neutral |
| 08/07/2020 | 235.57% | SVB Leerink | $14 → $10 | Maintains | Market Perform |
| 06/25/2020 | 202.01% | B of A Securities | → $9 | Reinstates | → Underperform |
| 05/20/2020 | 436.91% | Cantor Fitzgerald | $14 → $16 | Maintains | Neutral |
| 12/06/2019 | 403.36% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 10/08/2019 | 168.46% | Goldman Sachs | $24 → $8 | Downgrades | Neutral → Sell |
| 08/09/2019 | 202.01% | Barclays | $21 → $9 | Maintains | Underweight |
| 05/10/2019 | 705.37% | Citigroup | → $24 | Downgrades | Buy → Neutral |
| 05/10/2019 | 571.14% | Cantor Fitzgerald | $57 → $20 | Downgrades | Overweight → Neutral |
| 03/01/2019 | 2248.99% | Citigroup | $67 → $70 | Maintains | Buy |
| 01/17/2019 | — | Leerink Swann | Initiates Coverage On | → Market Perform | |
| 01/03/2019 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 11/19/2018 | 839.6% | Goldman Sachs | $36 → $28 | Upgrades | Sell → Neutral |
| 11/02/2018 | 671.81% | JP Morgan | $83 → $23 | Maintains | Underweight |
| 11/02/2018 | 1577.85% | Cantor Fitzgerald | $75 → $50 | Maintains | Overweight |
| 11/02/2018 | 873.15% | Barclays | $72 → $29 | Downgrades | Equal-Weight → Underweight |
| 11/02/2018 | 671.81% | JP Morgan | $83 → $23 | Downgrades | Overweight → Underweight |
| 10/01/2018 | 2416.78% | Cantor Fitzgerald | → $75 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/20/2023 | 168.46% | HC Wainwright公司 | →$8 | 重申 | 购买→购买 |
| 08/04/2023 | 168.46% | HC Wainwright公司 | →$8 | 重申 | 购买→购买 |
| 06/05/2023 | 168.46% | HC Wainwright公司 | →$8 | 重申 | 购买→购买 |
| 05/05/2023 | 168.46% | HC Wainwright公司 | →$8 | 重申 | →购买 |
| 03/06/2023 | 168.46% | HC Wainwright公司 | →$8 | 重申 | →购买 |
| 08/05/2022 | 168.46% | HC Wainwright公司 | $12→$8 | 维护 | 买 |
| 05/06/2022 | 302.68% | HC Wainwright公司 | $14→$12 | 维护 | 买 |
| 09/28/2021 | - | 花旗集团 | 升级 | 中性→购买 | |
| 08/06/2021 | 168.46% | 高盛 | $9→$8 | 维护 | 卖 |
| 08/06/2021 | 101.34% | 加拿大皇家银行资本 | $13→$6 | 维护 | 行业表现 |
| 2020/08/10 | 302.68% | 花旗集团 | $14→$12 | 维护 | 中性 |
| 08/07/2020 | 235.57% | SVB Leerink | $14→$10 | 维护 | 市场表现 |
| 06/25/2020 | 202.01% | B of A证券 | →$9 | 恢复 | →表现不佳 |
| 05/20/2020 | 436.91% | 康托·菲茨杰拉德 | $14→$16 | 维护 | 中性 |
| 2019年6月12日 | 403.36% | HC Wainwright公司 | →$15 | 开始承保 | →购买 |
| 2019年10月08日 | 168.46% | 高盛 | $24→$8 | 评级下调 | 中性→销售 |
| 2019年08月09日 | 202.01% | 巴克莱 | $21→$9 | 维护 | 体重不足 |
| 2019年5月10日 | 705.37% | 花旗集团 | →$24 | 评级下调 | 购买→中性 |
| 2019年5月10日 | 571.14% | 康托·菲茨杰拉德 | $57→$20 | 评级下调 | 超重→中性 |
| 2019年03月01日 | 2248.99% | 花旗集团 | $67→$70 | 维护 | 买 |
| 2019年01月17日 | - | 利林克·斯旺 | 开始承保 | →市场表现 | |
| 2019年03月01日 | - | 古根海姆 | 评级下调 | 购买→中性 | |
| 2018年11月19日 | 839.6% | 高盛 | $36→$28 | 升级 | 卖出→中性 |
| 11/02/2018 | 671.81% | 摩根大通 | $83→$23 | 维护 | 体重不足 |
| 11/02/2018 | 1577.85% | 康托·菲茨杰拉德 | $75→$50 | 维护 | 超重 |
| 11/02/2018 | 873.15% | 巴克莱 | $72→$29 | 评级下调 | 等重→减码 |
| 11/02/2018 | 671.81% | 摩根大通 | $83→$23 | 评级下调 | 增持→减持 |
| 10/01/2018 | 2416.78% | 康托·菲茨杰拉德 | →$75 | 开始承保 | →超重 |
What is the target price for Puma Biotechnology (PBYI)?
彪马生物科技(PBYI)的目标价是多少？
The latest price target for Puma Biotechnology (NASDAQ: PBYI) was reported by HC Wainwright & Co. on September 20, 2023. The analyst firm set a price target for $8.00 expecting PBYI to rise to within 12 months (a possible 168.46% upside). 5 analyst firms have reported ratings in the last year.
纳斯达克(Sequoia Capital：PBYI)的最新目标价由HC Wainwright&Co.于2023年9月20日报道。这家分析公司将目标价定为8美元，预计PBYI将在12个月内升至(可能上涨168.46%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Puma Biotechnology (PBYI)?
彪马生物科技(PBYI)的最新分析师评级是多少？
The latest analyst rating for Puma Biotechnology (NASDAQ: PBYI) was provided by HC Wainwright & Co., and Puma Biotechnology reiterated their buy rating.
纳斯达克(Sequoia Capital：PBYI)的最新分析师评级由HC Wainwright&Co.提供，彪马生物科技重申其买入评级。
When is the next analyst rating going to be posted or updated for Puma Biotechnology (PBYI)?
彪马生物科技(PBYI)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Puma Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Puma Biotechnology was filed on September 20, 2023 so you should expect the next rating to be made available sometime around September 20, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与彪马生物科技的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。彪马生物技术的上一次评级是在2023年9月20日提交的，所以你应该预计下一次评级将在2024年9月20日左右的某个时候公布。
Is the Analyst Rating Puma Biotechnology (PBYI) correct?
分析师对彪马生物科技(PBYI)的评级正确吗？
While ratings are subjective and will change, the latest Puma Biotechnology (PBYI) rating was a reiterated with a price target of $0.00 to $8.00. The current price Puma Biotechnology (PBYI) is trading at is $2.98, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的彪马生物技术(PBYI)评级被重申，目标价在0.00美元至8.00美元之间。彪马生物科技(PBYI)目前的交易价格为2.98美元，在分析师的预测范围内。